Admilparant for treating idiopathic pulmonary fibrosis

Admilparant is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) in adults. IPF is a chronic (long-term) disease of the lungs characterised the slow build-up of scar tissue. This causes the lungs to become inflamed and thick making it harder for them to work normally. This reduces how much oxygen moves from the air into the blood. IPF is associated with a gradual decline in lung function, slow respiratory failure, and a high death rate. Several treatments can slow the worsening of IPF, but there is currently no treatment that can stop or reverse the scarring of the lungs.